Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. - Wikidata - awgldk - TriplyDB

Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

http://www.wikidata.org/entity/Q42689963

about

Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis An Algorithm and R Program for Fitting and Simulation of Pharmacokinetic and Pharmacodynamic Data.An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment.Change in erythropoietin pharmacokinetics following hematopoietic transplantation.Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.Application of quantitative pharmacology in development of therapeutic monoclonal antibodies Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys Modelling chemotherapy effects on granulopoiesis.Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans.Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT.Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.Development of biosimilars--pharmacokinetic and pharmacodynamic considerations.PK-PD modeling of protein drugs: implications in assay development.Pharmacokinetics and pharmacodynamics of pegfilgrastim.Lifespan based indirect response models.Toward a universal treatment for cancer: cell inflation assisted chemotherapy.Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384.Pharmacodynamic models of age-structured cell populations.Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview.Understanding, treating and avoiding hematological disease: better medicine through mathematics?Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy.Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects.Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy.Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals.Model-Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab.Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?

P2860

Q24632145-776AD78B-E95E-4235-9841-638E71E67F39 Q27004054-BCB5EE89-AE5D-4DDB-B13B-7AC31EABA83A Q28533979-D6C504E3-BE94-45AF-9E65-F65171F83259 Q31119393-E6E8116C-13BA-49E1-8E1E-436DA4791860 Q33412963-A2C530E3-4DDB-4C34-9B58-350FC825571B Q33427607-CBF64340-63D3-4B86-9B5D-2AF93FEE70A4 Q33589591-93744D7B-1079-4BBC-87DF-44AB34220A5A Q33712928-88FC1AB7-776E-42EC-BFAB-C56D915BE7F7 Q33892534-349BD18D-B1A1-4D1A-B77A-67969F2457D7 Q34293586-08C3AAD3-489E-4C53-8036-A9B52117876C Q34293689-EA3CA4F9-4798-4C4C-A5C5-0E74D193055B Q34293733-51D2CCD7-27B2-4963-9DA6-EF0C9AB905A2 Q34996295-D8375CB6-E4C3-4ADD-8943-73CF6CBCE0D2 Q35132886-0C23A73A-565C-49E8-B121-64886A1B67B7 Q35168311-C95529A5-23DF-4DDF-8376-A832C1E47B6B Q35226129-53629E98-88A9-489C-BC0B-0CD835A5F7E5 Q35595803-965630D3-A4A1-4BDE-B6B4-1C3F54C2BFFE Q36427261-C9EDFFE4-658A-4B24-A518-12779617C021 Q37170126-F2D1DC9F-25CF-4D80-9637-BC477E745285 Q37421288-845E102A-2E02-437C-8F44-BE08E0F85986 Q37455829-26438A7E-AFED-4515-8E40-F69F71523EE1 Q37676066-EAB7F0F7-A1DE-45F5-85BD-D319381BBD31 Q37854638-34469077-9B03-4774-ADD6-8485DA729DD7 Q37860299-66C2F815-9E3D-41F1-9DD8-AD66F0104530 Q37972792-7DC4BB42-F1CB-4451-94F3-4277A5AF42E5 Q38155169-A44680D2-7604-4621-B2C3-3536BBC8A9F8 Q38452569-0F5D07E1-A448-4ED1-8DDC-2C86BC2E34FA Q38588105-542848E4-1FE9-424A-9684-8D6DBF6C0C07 Q38917756-54106079-B66F-4A12-8EEF-9DFC9E6339AA Q41742420-DA0DEC74-28F3-4D65-AE92-52543129E926 Q42632652-EEE63AEF-9F2B-4F03-AAB8-E84A47E6D7EF Q43635728-9211337F-3799-491C-A73E-A5EE0FC68449 Q44019603-577A4A00-AD38-45E0-9236-921CD1B3CDB1 Q44799963-8A819B13-48CD-4987-A359-DF37E234E376 Q46028013-23AF042F-9C68-4460-BEBE-F74A85F7C237 Q46358056-578C7F06-647F-449E-942A-690CF5EAC002 Q49447486-91DB8891-B747-4858-90D4-1996D4694CAA Q50698378-EC0195EC-6AC9-4663-9FDC-D9CFF88DFFD3 Q50878372-EAEB7D72-AD10-40FF-9E23-D1FC097ECD3C Q58416012-AA7B86C6-86D4-489F-8BF8-3850BCAE4025

P2860

Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

http://www.wikidata.org/entity/Q42689963

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

@en

Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

@nl

type

label

Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

@en

Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

@nl

prefLabel

Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

@en

Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

@nl

P1433

Q42689963-588E9E83-40A8-4F74-8B4B-FE39D87549C9

P1476

Q42689963-3B1FD628-495C-4037-B8BE-893E465BCD98

P2093

Q42689963-582E4507-0C5B-4B2F-878D-97557BFB8F0D

Q42689963-B921EFDC-1C6B-43E3-9DF1-38B6E79DB386

Q42689963-C0042AEE-7C1F-494B-B5E7-0C179B461B49

Q42689963-DF95F813-A591-47F6-BE12-DF562336F13E

Q42689963-FDB2F06B-92B9-4CAF-A7B6-F1DFE8EECE4D

P2860

Q42689963-05DFD9A7-6799-42E1-9F62-2510047FF01D

Q42689963-19203DC3-7043-43F5-807B-6E735767398A

Q42689963-1B0D5C93-7E3E-400A-9FBD-10C9B6D53009

Q42689963-4C35BA67-9A99-46CA-97D5-1B5D3B0686DD

Q42689963-554C539C-F223-49A5-A58B-03A3FAD89FB6

Q42689963-8CF29DD2-A166-4E50-AC5D-E21975E3273D

Q42689963-99685D04-28A0-48C0-886C-D323B4C5F9BD

Q42689963-E628878F-14F9-4AD1-87F0-C86A8027CCA8

Q42689963-EBB305A6-AE8A-4ECF-81F9-3C59B4F78A92

Q42689963-ED1E6E20-B0FD-42FD-B3DA-D47DD7223244

P304

Q42689963-8467C387-075C-4FF7-8ED4-46B3006D7C6C

P31

Q42689963-DE9862EA-4CDA-4301-8BE6-C0E0A8B50046

P356

Q42689963-39859EF3-976C-44B2-B9A8-63E499739C9D

P433

Q42689963-5DA310A3-8D11-40BA-A39F-47F64FFD5C8A

P478

Q42689963-18A65496-70DF-4443-A607-257AFCCFB6AB

P577

Q42689963-3A6502FF-4470-495A-96F6-3ACA2743992B

P5875

Q42689963-171A9B1E-4327-4652-A41C-BBF00F311F16

P698

Q42689963-5EDF8526-FE53-4B16-A9FE-DD4A7620CBD5

P356

0091270006288731

P1433

The Journal of Clinical Pharmacology

P1476

Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

@en

P2093

Bing-Bing Yang

http://www.w3.org/2001/XMLSchema#string

Gisela Schwab

http://www.w3.org/2001/XMLSchema#string

Lorin K Roskos

http://www.w3.org/2001/XMLSchema#string

Pamela Lockbaum

http://www.w3.org/2001/XMLSchema#string

Peggy Lum

http://www.w3.org/2001/XMLSchema#string

P2860

Neutrophil kinetics in the dog

Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy.

Mono-N-terminal poly(ethylene glycol)-protein conjugates.

Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats.

Cell-cell signalling in the regulation of blood cell formation and function.

Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection.

Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers.

P304

747-757

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270006288731

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6974682

http://www.w3.org/2001/XMLSchema#string

P698

16809800

http://www.w3.org/2001/XMLSchema#string